Track the GYRE THERAPEUTICS, INC. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €708.3m. The latest transaction was disclosed on 11 June 2026 (Levée d'options). Among the most active insiders: Ma Songjiang. Every trade is accessible without an account.
58
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€771,487
45 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate GYRE THERAPEUTICS, INC. Strong Buy (bullish), based on 3 analysts. Average price target: US$18.67.
22Σ signal
Buys n/a€771,487 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 18,110 of 29,062 companies
44.4
score / 100
Value
26
Quality
63
FCF yld-0.1%
Earn yld0.7%
EV/EBITDA49.9x
ROE-17%
Gross mgn95%
Net mgn4.3%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
53 shares@ US$13.030.1% of flowCommon StockSEC:0001140361-25-008091:0
25 of 58 declarations
Acerca de GYRE THERAPEUTICS, INC.
GYRE THERAPEUTICS, INC. es una empresa centrada en el desarrollo de tratamientos innovadores para enfermedades neurodegenerativas. Cotiza en NASDAQ bajo el ticker GYRE.